AMSTERDAM, The Netherlands, April 8 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, is, as of today, part of the newly created Next Biotech Index of NYSE Euronext. "We are pleased that NYSE Euronext has selected our company for this index," said Ronald Lorijn, CEO of AMT. "The index will increase the visibility of listed biotech companies and will help investors to track the performance of our sector."
The index is published daily on http://www.euronext.com as well as major data vendors. The ticker symbol is BIOTK.
About Amsterdam Molecular Therapeutics
AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.
Certain statements in this press release are "forward-looking
statements" including those that refer to management's plans and
expectations for future operations, prospects and financial condition.
Words such as "strategy," "expects," "plans," "anticipates," "believes,"
"will," "continues," "estimates," "intends," "projects," "goals," "targets"
and other words of similar meaning are intended to identify such
forward-looking statements. Such statements are based on the current
expectations of the management of Amsterdam Molecular Therapeutics only.
Undue reliance should not be placed on these statements because, by their
nature, they are
|SOURCE Amsterdam Molecular Therapeutics B.V|
Copyright©2008 PR Newswire.
All rights reserved